Prognostic Factors and Outcomes of Acute Leukemias in the Era of Novel Therapies
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Hematology".
Deadline for manuscript submissions: closed (10 December 2020) | Viewed by 191
Special Issue Editor
Special Issue Information
Dear Colleagues,
The development of high-throughput sequencing technologies and the relentless pursuit of quality translational and clinical research has allowed us to understand the process of leukemogenesis driven by recurrent mutations and design therapies that target these mutations. As a result, the landscape of standard therapy for acute leukemias has remarkably changed, and only within the last few years, several new agents were approved in acute leukemias. Today, clinicians make therapy decisions not only based on patient-related factors but also on specific molecular and cytogenetic features. For example, in acute myeloid leukemia, underlying driver mutations have become one of the major determinants in therapy decisions. Patients with fms-like tyrosine kinase 3 or isocitrate dehydrogenase mutations are being treated with agents targeting these mutations. Similarly, detection of the Philadelphia chromosome and positivity of cell surface antigens, such as CD19, CD20, and CD22, have become essential parameters in therapy decisions for patients with acute lymphoblastic leukemia. However, despite all these achievements with novel chemotherapeutics, patients with acute leukemia still relapse. Hence, understanding the predictors of response and mechanisms of relapse has become crucial to developing superior treatment strategies. The present Special Issue aims to expand the knowledge on pathological and clinical characteristics, resistance mechanisms, and outcomes of patients with acute leukemia following treatment with novel agents.
Dr. Musa Yilmaz
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Early response assessment in acute leukemias
- Role of minimal residual disease (flow cytometry, polymerase chain reaction)
- Impact of cytogenetic, genomic and other prognostic factors
- Novel therapeutic strategies in acute lymphoblastic leukemia
- Novel therapeutic strategies in acute myeloid leukemia
- Prognosis and treatment of older adults with acute leukemias
- Toxicities of recently approved novel chemotherapeutics
- Stem cell transplantation in acute leukemias
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
